These findings suggested that PTEN‐negative status, indicated by a staining score of 0, predicted a better prognosis in ICC patients treated with bortezomib (p = .020 and .017, respectively) (Figure 4E,F). This evidence concerns the gene PTEN and intrahepatic cholangiocarcinoma.